A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 97 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-19.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 37th largest by enrollment, is one of 21 that started in 2012, is one of 45 in phase 3, and was the 65th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 21 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 279 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 179th largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2012, is one of 187 in phase 3, and was the 311th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment.
The trial medication will be add-on to the subject's stable pre-trial OAD and/or insulin regimen.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 279 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide
Drug: placebo
1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)
Calculated as the estimated mean change from baseline in HbA1c (%) after 26 Weeks of treatment based on the statistical model.
Time frame: Week 0, Week 26
Estimated Proportion of Responders Achieving HbA1c <7.0% and no Weight Gain After 26 Weeks of Treatment
Calculated as estimated percentage of subjects achieving HbA1c \<7.0% and no weight gain after 26 weeks of treatment based on the statistical model.
Time frame: At week 26
Estimated Proportion of Responders Achieving HbA1c <7.0% and no Minor or Severe Hypoglycaemic Episodes After 26 Weeks of Treatment
Calculated as estimated percentage of subjects achieving HbA1c \<7.0% and no minor or severe hypoglycaemic episodes observed within 26 weeks of treatment based on the statistical model.
Time frame: At week 26
Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Self-measured Plasma Glucose (SMPG) 7-point Profiles
SMPG was measured before and 90 minutes after breakfast, lunch and dinner and at bedtime at Week 0, 12 and 26. A summary measure of the 7 values was derived for each applicable visit as the area under the curve divided by the period of time elapsed between the first and last measurement. The change from baseline to week 26 was estimated using the statistical model.
Time frame: Week 0, week 26
Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Body Mass Index (BMI)
Calculated as estimated mean change in BMI (kg/m˄2) from baseline to Week 26 based on the statistical model.
Time frame: Week 0, week 26
Estimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula)
Calculated as the estimated ratio to baseline in eGFR (mL/min/1.73m˄2) after 26 Weeks of treatment based on the statistical model.
Time frame: Week 0, week 26
This trial was conducted in France, Poland, Russian Federation, Ukraine, United Kingdom, and the United States of America.
| Milestone | Lira 1.8 mg | Placebo |
|---|---|---|
| Started | 140 | 139 |
| Exposed | 140 | 137 |
| Completed | 105 | 105 |
| Not completed | 35 | 34 |
| Withdrew: Adverse event | 17 | 4 |
| Withdrew: Protocol violation | 0 | 3 |
| Withdrew: Withdrawal criteria | 17 | 25 |
| Withdrew: Unclassified | 1 | 2 |
Calculated as the estimated mean change from baseline in HbA1c (%) after 26 Weeks of treatment based on the statistical model.
| percentage (%) | Lira 1.8 mg | Placebo |
|---|---|---|
| Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin) | -1.05 ± 0.8944 | -0.38 ± 0.8797 |
Calculated as estimated percentage of subjects achieving HbA1c \<7.0% and no weight gain after 26 weeks of treatment based on the statistical model.
| percentage of patients | Lira 1.8 mg | Placebo |
|---|---|---|
| Estimated Proportion of Responders Achieving HbA1c <7.0% and no Weight Gain After 26 Weeks of Treatment | 46.03 | 15.99 |
Calculated as estimated percentage of subjects achieving HbA1c \<7.0% and no minor or severe hypoglycaemic episodes observed within 26 weeks of treatment based on the statistical model.
| percentage of patients | Lira 1.8 mg | Placebo |
|---|---|---|
| Estimated Proportion of Responders Achieving HbA1c <7.0% and no Minor or Severe Hypoglycaemic Episodes After 26 Weeks of Treatment | 33.23 | 11.23 |
SMPG was measured before and 90 minutes after breakfast, lunch and dinner and at bedtime at Week 0, 12 and 26. A summary measure of the 7 values was derived for each applicable visit as the area under the curve divided by the period of time elapsed between the first and last measurement. The change from baseline to week 26 was estimated using the statistical model.
| mmol/L | Lira 1.8 mg | Placebo |
|---|---|---|
| Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Self-measured Plasma Glucose (SMPG) 7-point Profiles | -1.59 ± 2.480 | -0.51 ± 2.391 |
Calculated as estimated mean change in BMI (kg/m˄2) from baseline to Week 26 based on the statistical model.
| kg/m^2 | Lira 1.8 mg | Placebo |
|---|---|---|
| Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Body Mass Index (BMI) | -0.88 ± 1.3214 | -0.38 ± 1.1679 |
Calculated as the estimated ratio to baseline in eGFR (mL/min/1.73m˄2) after 26 Weeks of treatment based on the statistical model.
| mL/min/1.73m˄2 | Lira 1.8 mg | Placebo |
|---|---|---|
| Estimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula) | 0.99 ± 0.17 | 1.01 ± 0.19 |
Collected over The adverse events were collected from Week 0 to Week 27±3 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lira 1.8 mg | — | 14/140 (10%) | 73/140 (52.1%) |
| Placebo | — | 15/137 (10.9%) | 49/137 (35.8%) |
| Event | Lira 1.8 mg | Placebo |
|---|---|---|
| SyncopeNervous system disorders | 2/140 | 0/137 |
| AnaemiaBlood and lymphatic system disorders | 0/140 | 1/137 |
| Acute myocardial infarctionCardiac disorders | 1/140 | 1/137 |
| Abdominal pain lowerGastrointestinal disorders | 0/140 | 1/137 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/140 | 1/137 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/140 | 1/137 |
| Autoimmune hepatitisHepatobiliary disorders | 0/140 | 1/137 |
| Arteriosclerotic gangreneInfections and infestations | 0/140 | 1/137 |
| OsteomyelitisInfections and infestations | 0/140 | 1/137 |
| FallInjury, poisoning and procedural complications | 0/140 | 1/137 |
| Event | Lira 1.8 mg | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 30/140 | 6/137 |
| Lipase increasedInvestigations | 21/140 | 12/137 |
| VomitingGastrointestinal disorders | 17/140 | 3/137 |
| NasopharyngitisInfections and infestations | 7/140 | 16/137 |
| DiarrhoeaGastrointestinal disorders | 10/140 | 4/137 |
| Glomerular filtration rate decreasedInvestigations | 9/140 | 7/137 |
| Renal impairmentRenal and urinary disorders | 7/140 | 8/137 |
| ConstipationGastrointestinal disorders | 8/140 | 2/137 |
| Upper respiratory tract infectionInfections and infestations | 4/140 | 7/137 |
| HeadacheNervous system disorders | 7/140 | 4/137 |
| Age, Continuous(years) | Lira 1.8 mg | Placebo | Total |
|---|---|---|---|
| Mean | 68.0 ± 8.3 | 66.3 ± 8.0 | 67.2 ± 8.2 |
| Sex: Female, Male(Participants) | Lira 1.8 mg | Placebo | Total |
|---|---|---|---|
| Female | 65 | 72 | 137 |
| Male | 75 | 65 | 140 |
| Fasting plasma glucose (FPG)(mmol/L) | Lira 1.8 mg | Placebo | Total |
|---|---|---|---|
| Mean | 9.48 ± 3.270 | 9.27 ± 2.842 | 9.38 ± 3.061 |
| Glycosylated haemoglobin (%)(HbA1c)(Percent (%) glycosylated haemoglobin) | Lira 1.8 mg | Placebo | Total |
|---|---|---|---|
| Mean | 8.08 ± 0.792 | 8.00 ± 0.853 | 8.04 ± 0.823 |
Ran from Jun 2012 to primary completion in Aug 2013, 14 months.
Results were first posted in Oct 2014, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 14 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide